- Home
- IIM vs CSTL Comparison
IIM vs CSTL Comparison
Compare IIM & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIM
- CSTL
- Stock Information
- Founded
- IIM 1993
- CSTL 2007
- Country
- IIM United States
- CSTL United States
- Employees
- IIM N/A
- CSTL 761
- Industry
- IIM Investment Managers
- CSTL Medical Specialities
- Sector
- IIM Finance
- CSTL Health Care
- Exchange
- IIM Nasdaq
- CSTL Nasdaq
- Market Cap
- IIM 551.6M
- CSTL 558.7M
- IPO Year
- IIM N/A
- CSTL 2019
- Fundamental
- Price
- IIM $12.08
- CSTL $16.79
- Analyst Decision
- IIM
- CSTL Strong Buy
- Analyst Count
- IIM 0
- CSTL 6
- Target Price
- IIM N/A
- CSTL $38.33
- AVG Volume (30 Days)
- IIM 122.2K
- CSTL 540.5K
- Earning Date
- IIM 01-01-0001
- CSTL 05-05-2025
- Dividend Yield
- IIM 4.63%
- CSTL N/A
- EPS Growth
- IIM N/A
- CSTL N/A
- EPS
- IIM 0.02
- CSTL N/A
- Revenue
- IIM N/A
- CSTL $347,083,000.00
- Revenue This Year
- IIM N/A
- CSTL N/A
- Revenue Next Year
- IIM N/A
- CSTL $3.14
- P/E Ratio
- IIM $591.50
- CSTL N/A
- Revenue Growth
- IIM N/A
- CSTL 38.43
- 52 Week Low
- IIM $9.94
- CSTL $15.70
- 52 Week High
- IIM $12.32
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- IIM 63.25
- CSTL 31.31
- Support Level
- IIM $11.64
- CSTL $15.70
- Resistance Level
- IIM $12.05
- CSTL $17.70
- Average True Range (ATR)
- IIM 0.13
- CSTL 1.06
- MACD
- IIM 0.06
- CSTL -0.36
- Stochastic Oscillator
- IIM 98.48
- CSTL 15.25
About IIM Invesco Value Municipal Income Trust
Invesco Value Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide common shareholders with current income which is exempt from federal income tax.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.